The 24-h FEV(1) time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

ABSTRACT: These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV(1)) profile of once-daily (QD) olodaterol compared to placebo and twice-daily (BID) formoterol in patients with moderate to very severe chronic obstructive pulmonary disease. In two replicate, randomized, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Gregory J, Bernstein, Jonathan A, Hamilton, Alan, Nivens, Michael C, Korducki, Lawrence, LaForce, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152473/
https://www.ncbi.nlm.nih.gov/pubmed/25187881
http://dx.doi.org/10.1186/2193-1801-3-419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152473/
https://www.ncbi.nlm.nih.gov/pubmed/25187881
http://dx.doi.org/10.1186/2193-1801-3-419

Ejemplares similares